1.Self-management behavior and health-related quality of life in Chinese hemodialysis patients
Chinese Journal of Tissue Engineering Research 2005;9(11):192-194
BACKGROUND: It has been shown that patients managed with hemodialysis experience decrease of quality of life. But there are a few reports about the relationship between the self-management behavior such as dietary behavior, taking medicine, management behavior of physical sign etc and health-related quality of life (HRQOL) in hemodialysis patients.OBJECTIVE: To study the relationship between self-management behavior and HRQOL in Chinese hemodialysis patients,especially potential association of self-management behavior variables with indicators of HRQOL in order to improve their quality of life (QOL).DESIGN: Sampling investigation based on hemodialysis patients.SETTING: Nursing department and dialysis center in a university hospital. PARTICIPANTS: This research was completed in the Nursing Department of First Hospital Affiliated to China Medical University. Totally 120hemodialysis patients,63 males and 57 females,aged 19 -79 years old with the mean age of(52 ± 12),were selected from the First and Second Hospital Affiliated to China Medical University,the First Affiliated Hospital of Dalian Medical University,the Central and the Second Hospital of Shenyang Medical College,from July to September 2003. Inclusion criteria: Patients above 18years old,dialysis history more than 3 months with twice or three times every week,understanding the questionnaires and being volunteers. Exclusion criteria: Patients with acute disease and mental disorder.METHODS: Self-administered questionnaire was used to measure self-management behavior and short-form 36 health survey(SF-36) was used to measure HRQOL of patients with hemodialysis. Correlation and multivariate regression analysis were used to test the relationship between self-management behavior and HRQOL.MAIN OUTCOME MEASURES: Self-management behavior and HRQOL.RESULTS: Totally 107 questionnaires were available. Multivariate regression analysis indicated that management of physical,psychosocial activity was the significant factor of.physical component summary(regression coefficient = 2.709,R2 =0. 150,P<0.01),and management of physical sign,psychosocial behavior was the significant factor of mental component summary(regressioncoefficient=1.126,R2=0.041,P<0.05).CONCLUSION: Improving hemodialysis patients' management of physical,psychosocial activity and management of physical sign could help hemodialysis patients to raise their HRQOL.
2.The screening and polymorphic analysis of bovine tetranucleotide STR loci
Aiping CHEN ; Xiaoyan MA ; Hongyu SUN
Chinese Journal of Forensic Medicine 2009;24(6):361-364
Objective To screen the microsatellites with low occurrence rate of stutter band and establish the effective bovine STR typing system.Methods The tetranucleotide STR loci in bovine genome were searched with Tandem Repeat Finder software.Primers were designed and used to amplify these candidate loci and the PCR products were separated with electrophoresis.DNA samples from 100 head of unrelated cattle were typed.Results Among these candidate loci,6 bovine tetranucleotide STR loci showed high polymorphism,and their CDP and CPE value were 0.99995 and 0.859591 respectively.Conclusion The 6 bovine tetranucleotide STR loci can be used for bovine identification and parentage testing.
3.Use of different diagnostic criteria of metabolic syndrome in health check-up receivers from one state-owned enterprise in Beijing
Erman LI ; Aijuan MA ; Aiping LIU ; Peiyu WANG ; Ming LI
Chinese Journal of Health Management 2010;04(3):164-167
Objective To compare the diagnostic criteria of metabolic syndrome(MS) developed by the International Diabetes Federation(IDF) in 2005,the 3th Report of National Cholesterol Education Program-Adult Treatment Panel Ⅲ(NCEP-ATP Ⅲ) in 2005,and the Chinese Diabetes Society(CDS) in 2004.Methors A total of 1039 adults aged 23 to 62 year-old were enrolled in this epidemiological investigation to assess the prevalence of MS by above three definitions.Results The MS prevalence rate was 14.8%,14.2% and 10.7% in ATPⅢ,IDF,and CDS,respectively.The diagnoses agreement of IDF with ATPⅢ was stronger(Kappa=0.912) than IDF with CDS(Kappa=0.466) and ATPⅢ with CDS (Kappa=0.504).CDS definition found 5.7% of non-MS individuals had risk factor accumulation.Those defined by ATPⅢ and IDF criteria were presented with central obesity + ypertriglyceridemia + abnormal blood pressure and central obesity + hypertriglyceridemia + low hish-density lipoprotein hyperlipidemia.However,those defined by CDS criterion were commonly presented with obesity + hypertriglyceridemia + abnormal blood pressure or obesity + hypertriglyceridemia + hyperglycemia.Conclusions The agreement of IDF and ATPⅢ definition was relatively stronger.For better screening sensitivity,those three criteria,or CDS and IDF criteria,or CDS and ATPⅢ criteria should be used together.
4.THE EFFECT OF GOSSYPOL ON K~+, Na~+ AND TESTOSTERONE IN SERUM AND RAT TESTIS FLUID IN RATS
Jiansun TONG ; Aiping QI ; Ru WANG ; Jianjun MA ; Shaozhen QIAN
Chinese Pharmacological Bulletin 1986;0(05):-
Feeding adult male rats with gossypol acetic acid at a dose of 15 nig/kg/day for 50 days led to infertility. Spermatogenesis and sperm motility were impaired ( table 1 ) . However, testosterone, K+ and Na+ concentsrations in serum and RTF were found to be unchanged (table 2, 3 ) . It suggests that at low antifertility doses gossypol disrupts spermatogenesis in the seminiferous epithelium without affecting testosterone, K+ and Na+ secretion and translation in testis.
5.Preliminary report of dosage-escalated sorafenib in patients with metastatic renal cell carcinoma
Lu SI ; Jianhui MA ; Jinwan WANG ; Aiping ZHOU ; Jun GUO
Chinese Journal of Urology 2009;30(1):18-20
Objective To evaluate the safety and efficacy of dosage-escalated sorafenib in pa-tients with metastatic renal cell carcinoma. Methods Twelve male patients and 4 female patients with median age of 53 (37-71 years) were included in this study. They were with refractory meta-static renal-clear-cell carcinoma and received sorafenib from 800 mg/d to 1200mg/d or 1800 mg/d gradually until intolerable or disease progression occurred. Overall response rate, toxicity and progres-sion free survival (PFS) were recorded and analyzed. Results The median follow-up was 11 months (9-16 months). The overall rate of objective response and disease control rate were 44%(7/16)and 81%(13/16), respectively. Serious adverse effects (≥Grade Ⅲ) included hand-foot skin reaction (25%, 4/16), mucositis (19%, 3/16), diarrhea (19%, 3/16), hypertension (12%, 2/16) and my-elosuppression (12%, 2/16). PFS for high risk patient was 9.2 months at the end of this study. Conclusions The dosage-escalated sorafenib could obtain a high response rate and prolong PFS of high-risk patients. The toxicities are tolerable for metastatic renal cell carcinoma patients treated with sorafenib.
6.Phase Ⅱ study of sorafenib as first line treatment in patients with metastatic renal cell carcinoma
Chuanliang CUI ; Jianhui MA ; Jun GUO ; Aiping ZHOU ; Jinwan WANG
Chinese Journal of Urology 2009;30(1):15-17
Objective To evaluate the safety and efficacy of sorafenib as first line treatment in patients with metastatic renal cell carcinoma. Methods Eleven patients with metastatic renal cell carcinoma after radical nephrectomy and 1 patient with locally advanced renal cell carcinoma and unre-sectable primary renal tumor were eligible for this study. The regimen was oral intake of sorafenib (400 mg twice daily) until the disease progression or toxicity becoming intolerable. Results All pa-tients were evaluable for response and toxicity assessment. The overall objective response rate and dis-ease control rate were 25%(3/12) and 83%(10/12, 3 partial responses and 7 disease stabilizations). The actuarial 6-month progression-free survival was 83% (10/12), while the median survival time was 16 months. The most common adverse effects included hand-foot skin reaction, rash, alopecia and hy-pertension. Conclusion Sorafenib is effective and safe as first line treatment for patients with meta-static renal cell carcinoma.
7.Effect of Naotan Ⅰ on Orphans with Cerebral Palsy from Welfare Houses
Zhaopu SONG ; Yipeng SONG ; Aiping WANG ; Shuaitong MA
Chinese Journal of Rehabilitation Theory and Practice 2011;17(3):280-282
ObjectiveTo investigate the clinical effect of Chinese Medicine Naotan Ⅰ on cerebral palsy. Methods120 orphans with cerebral palsy from welfare houses were divided into experimental group and control group. The former took Naotan Ⅰ and the latter took piracetam. ResultsThe total effective rate was 93.33% in the experimental group and 78.67% in the control group (P<0.05).ConclusionNaotan Ⅰ is effective on cerebral palsy of children.
8.Risk prediction of diabetes in Chinese adults
Aijuan MA ; Aiping LIU ; Peiyu WANG ; Erman LI ; Shixin WANG ; Ming LI
Chinese Journal of Health Management 2012;06(4):220-223
Objective To evaluate the use and effectiveness of Human-Computer Interaction (HC1) -based risk prediction of diabetes among Chinese adults.MethodsHCI-based risk prediction of diabetes was performed in 639 non-diabetics aged 23 to 61years old.Risk prediction results,main risk factors of diabetes and helpful suggestions were reported and used for self-management.After l-year follow-up,the participants received another assessment to find the changes of disease risk and risk factors.Non-parametric or Chi-square test was used for comparison of continuous or categorical variables,respectively.Receiver Operating Characteristic (ROC) curve was used to calculate the sensitivity and specificity of HCI.Results After1-year follow-up,the incidence of diabetes per year was1.4%,and all newly diagnosed diabetes was found in high-risk individuals.The proportion of high-risk individuals was 56.8% and 57.9%before and after follow-up ( x2 =0.36,P > 0.05 ).In comparison with baseline,average risk score of high-risk individuals was significantly declined ( 2.25 vs 2.91,Z =- 4.32,P < 0.05 ).Oversized waist circumstance,higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) was identified in 76.2%,36.2% and 3.8% of high risk individuals at1year,lower than those of baseline ( 87.3%,42.2% and12.4%,respectively ; x2 values were 30.56,6.05 and 22.26,respectively; all P <0.05) ; although the prevalence of hypertension was higher (23.5% vs18.1%,x2 =11.11,P<0.05).Conclusions HCI and effective control of risk factors could prevent the development of diabetes in high risk individuals.
9.Clinical study of sorafenib for patients with advanced renal cell carcinoma
Xin ZHAO ; Jianzhong SHOU ; Aiping ZHOU ; Chunxia DU ; Yongkun SUN ; Jinwan WANG ; Jianhui MA
Chinese Journal of Urology 2010;31(1):8-11
Objective To evaluate the safety and efficacy of sorafenib for patients with advanced stage renal cell carcinoma.Methods The clinical data of 85 patients with advanced renal cell carcinoma were reviewed.These patients were treated by sorafenib 400 mg Bid,dose escalation of sorafenib(400 mg Bid 1-4 weeks;600 mg Bid 5-8 weeks;800 mg Bid since then) or sorafenib 400 mg Bid+NF-α,respectively,until intolerance or disease progression occurred.The primary end points were objective response,disease control rate and adverse effects rate.Results The data of 80 patients can be evaluated.The median follow-up duration was 72 weeks (4-108 weeks).One patient (1.2%) reached complete remission(CR),17 cases(21.2%) reached partial remission(PR),50 cases (62.5%) maintained stable disease (SD),and 12 cases (15%) progressed.The objective response (CR+PR) was 22.5%,disease control rate (CR+PR-SD)was 85.0%.By May 2009,only 18 patients died,progression free survival and overall survival were not available.The common side effects included hand-foot skin reaction (55.0%),mucosa hemorrhage (52.5%),diarrhea(40.0%),lassitude (35.0%),anorexia(22.5%),mucosa ulcer(20.0%),hypertension(15.0%) and baldness(15.0%)etc.Most of these side effects could be released by symptomatic treatment.Conclusion Sorafenib has good short term effect for patients with advanced renal cell carcinoma and is well tolerated.
10.RADIOGRAPHIC MEASUREMENTS OF TALUS
Qinhua MA ; Qi CHEN ; Aiping LU ; Qi GUO ; Zhigang CHEN ; Zhizhon QIAN
Acta Anatomica Sinica 2002;0(05):-
Objective To investigate the rule of the talar growth and establish a normal radiographic measurement scale of the talus from postnatal infants to adults. Methods Radiographic measurements were performed with the lateral radiographs of right talus in 1*!765 normal cases(age 1 to 18). Results The talar growth velocity was the fastest before two years old.It was consistent with the development of physiques(e.g.height and weight),and then there was not a remarkable increase in the talar growth.At puberty,a temporal sudden increase was not found in the talus.Conclusion Radiographic measurements not only provide a normal contrast for the flats of the talus or the abnormal shapes caused by some congenital or acquired disease,but also was useful to the other subject(e.g.anthropology,forensic science).